Evidence Hub

Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release

Chancellor MB, Oefelein MG, Vasavada S

Neurourology and urodynamics, 2010

1,165 participants

Abstract

AIMS: Obesity is an established risk factor for urinary incontinence, yet no information exists as to the efficacy of antimuscarinic agents in this population. The goal of this study is to examine the efficacy of once daily trospium chloride (Sanctura) XR in overweight and obese patients with the overactive bladder syndrome.

METHODS: The primary and secondary end-points of the 1,165 study subjects from the integrated trospium chloride XR pivotal trials were stratified by World Health Organization (WHO) obesity levels I and II.

RESULTS: Obesity (WHO level I, II criteria) was associated with a more severe baseline OAB disease state (P < 0.01). Trospium chloride XR was more effective than placebo at reducing the primary endpoints (toilet voids, UUI, P < 0.0001) and at improving the secondary end-points (percent patients continent and urgency severity, P < 0.0001) for WHO obesity levels I and II.

CONCLUSIONS: Obesity is associated with a more severe OAB disease state. Once daily trospium chloride XR is efficacious in the obese patient with the OAB syndrome.

How strong is the evidence?

Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 1,165 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free